News and Events, Recent News

BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance

BERKELEY, Calif. and VANCOUVER, British Columbia, November 13, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today disclosed the allowance by the US Patent and Trademark Office (USPTO) and also the European Patent Office (EPO) of two patent […]

News and Events, Recent News

BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™

BERKELEY, Calif. and VANCOUVER, British Columbia, November 6, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinical update on its ongoing Phase I/IIa study of its lead vaccine candidate, BriaVax™, in advanced breast cancer patients. […]

News and Events, Recent News

FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax™ in Patients with Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Oct 30, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, announced today that the FDA has approved the roll-over combination study of BriaVax™ with pembrolizumab {Keytruda; manufactured by Merck & Co., Inc. (NYSE: MRK)} […]

Recent News

BriaCell Announces Warrant Incentive Program

Berkeley, CA and Vancouver, BC – October 13, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company“) (TSXV: BCT) (OTCQB: BCTXF) announced today that it is introducing a warrant exercise incentive program (the “Incentive Program“) designed to encourage the early exercise of up to approximately 26 million outstanding common share purchase warrants (the “Warrants “). […]

News and Events, Recent News

BriaCell Adds Third Clinical Site – Led by Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial in Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 25, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce the opening of a third clinical site. Jason Lukas, MD, PhD, a Board-Certified Oncologist – experienced with breast cancer vaccines […]

News and Events, Recent News

BriaCell Provides Research Update

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 14, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to provide an update on its collaborative and internal research as well as manufacturing activities. Collaborations The Company has recently initiated a […]

News and Events, Recent News

BriaCell Provides A Corporate Update

Berkeley, CA and Vancouver, BC – September 12, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is to provide a Corporate Update for the existing and potential shareholders. Dr. Williams, BriaCell’s President & CEO will provide an update on BriaVax™ […]